A Randomized Study of Two Dosing Regimens of Adagrasib in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation - 849-021

Mirati Therapeutics Inc.0 个研究点目标入组 262 人开始时间: 2023年5月25日最近更新: 2024年8月21日

适应症

试验速览

暂无简介。

•Are at least 18 years old (or old enough to legally make their own treatment decisions, according to local laws)., Have advanced NSCLC or metastatic NSCLC (NSCLC that started in the lungs and then spread to other parts of the body) with the KRAS G12C mutation., Have had previous treatment with 1) chemotherapy that included a drug called cisplatin or a drug called carboplatin and 2) a type of drug called an immune checkpoint inhibitor., Have recovered from their prior treatment and blood tests are within a safe range.

•Have had previous treatment with a drug that targets KRAS G12C., Have cancer that can potentially be removed with surgery., Patients with active brain metastases are eligible if 1) brain metastases are adequately treated and 2) are neurologically stable for at least 2 weeks prior to randomization., Steroid dosing >10 mg daily prednisone (or equivalent)., Have certain medical conditions or need to take certain medications that, in the opinion of a trial doctor, could make it unsafe for them to participate or difficult to complete the trial assessments, or are pregnant.

发起方